Swiss biotechnology company Araris Biotech completed its sale to Taiho Pharmaceutical. In connection with the deal BGPartner advised Araris on all Swiss legal matters, while Baker McKenzie represented the company with regard to all Swiss
Tags :BGPartner
BGPartner acted as legal advisor to Lafayette Mittelstand Capital on its acquisition of a majority stake in Diametal Group, a global leader in high-precision cutting tools, super abrasives, and wear parts. The transaction, which became
BGPartner has advised OrbiMed and Novo Holdings on Swiss legal matters related to the USD 200 million Series A financing of Windward Bio Group, a Swiss-based clinical-stage drug development company, advised by Homburger. The financing round
Swiss biotech company Alentis Therapeutics has successfully closed a $181.4 million oversubscribed Series D financing round, supported by a syndicate of top-tier biotech investors. The financing will support the company to develop a deep pipeline of
Memo Therapeutics, a late-stage biotech firm specializing in top-tier therapeutic antibodies, disclosed the successful conclusion of its CHF 25 million Series C funding round. This milestone was spearheaded by Pureos Bioventures, with strong participation from Memo
26 years after the demolition of the “Zur Linde” inn, a building permit has been granted. If all goes well, two new buildings will replace the gravel car park in the centre of the village from 2025.
In the pilot case of a PostFinance customer against PostFinance, the question is whether the customer must accept a negative balance on his account that arose due to a software error with the payment processor
GOLDBEK Holding, a fast growing and innovative German greeting card publishing company, has acquired 100% of ABC Kunst- und Glückwunschkartenverlag (its legal name is A. Boss & Co), a privately owned Swiss market leader in
Samsung Ventures has made a strategic investment in Araris Biotech. The investment corporation, that was established to promote the development of new technologies, has invested in the company in an independent deal ahead of its
Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system disorders, successfully closed an oversubscribed Series B financing round, raising CHF 103 mio (approx. USD 112 mio). The round was co-led by the European healthcare focused
